{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:09:34Z","timestamp":1782986974053,"version":"3.54.5"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.mcna.2009.08.016","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T02:07:30Z","timestamp":1259374050000},"page":"115-133","source":"Crossref","is-referenced-by-count":16,"title":["Safety Profile of IBD Therapeutics: Infectious Risks"],"prefix":"10.1016","volume":"94","author":[{"given":"Waqqas","family":"Afif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9613","key":"10.1016\/j.mcna.2009.08.016_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"9613","key":"10.1016\/j.mcna.2009.08.016_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(08)60285-8","article-title":"Initial combination therapy in early Crohn disease","volume":"371","author":"Sandborn","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mcna.2009.08.016_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn disease: the Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.gtc.2006.09.008","article-title":"Safety of infliximab and other biologic agents in the inflammatory bowel diseases","volume":"35","author":"Reddy","year":"2006","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mcna.2009.08.016_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn disease: Markov model analysis of a population-based cohort","volume":"117","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mcna.2009.08.016_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1542-3565(05)00759-7","article-title":"Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn disease","volume":"3","author":"Agrawal","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","article-title":"American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mcna.2009.08.016_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohn disease: a meta-analysis","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib17","article-title":"Azathioprine for maintaining remission of Crohn disease","author":"Pearson","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib18","article-title":"Azathioprine or 6-mercaptopurine for inducing remission of Crohn disease","author":"Sandborn","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mcna.2009.08.016_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000478.pub2","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib21","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","article-title":"Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Associate Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004836-200309000-00006","article-title":"Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn disease and ulcerative colitis","volume":"37","author":"Warman","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"21","key":"10.1016\/j.mcna.2009.08.016_bib25","first-page":"935","volume":"90","author":"Marrie","year":"2001","journal-title":"Praxis (Bern 1994)"},{"issue":"10","key":"10.1016\/j.mcna.2009.08.016_bib26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.mcna.2009.08.016_bib27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn disease. The North American Crohn Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib30","first-page":"1730","article-title":"Methotrexate in Crohn disease: long-term efficacy and toxicity","volume":"95","author":"Lemann","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ibd.20405","article-title":"Use of methotrexate in refractory Crohn disease: the Edinburgh experience","volume":"14","author":"Din","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?","volume":"48","author":"McLean-Tooke","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mcna.2009.08.016_bib33","article-title":"Association of Methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry","author":"Greenberg","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ibd.20027","article-title":"Safety of biologic therapy","volume":"13","author":"Blonski","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"23","key":"10.1016\/j.mcna.2009.08.016_bib35","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mcna.2009.08.016_bib36","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S1","key":"10.1016\/j.mcna.2009.08.016_bib38","first-page":"5436","article-title":"Safety of infliximab and other Crohn disease therapies-TREAT registry data with nearly 24,575 patient years of follow-up","volume":"104","author":"Lichtenstein","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up","volume":"29","author":"Lees","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2009.08.016_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn disease","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"S1","key":"10.1016\/j.mcna.2009.08.016_bib44","first-page":"5436","article-title":"SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn disease na\u00efve to immunomodulators and biologic therapy","volume":"103","author":"Sandborn","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib45","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib47","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8920","key":"10.1016\/j.mcna.2009.08.016_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00054725-200403000-00002","article-title":"Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis","volume":"10","author":"Arts","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.mcna.2009.08.016_bib50","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cgh.2008.04.035","article-title":"Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis","volume":"6","author":"Maser","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2165\/00126839-200405020-00007","article-title":"Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody","volume":"5","year":"2004","journal-title":"Drugs R D"},{"issue":"18","key":"10.1016\/j.mcna.2009.08.016_bib52","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2009.08.016_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib60","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2008.01942.x","article-title":"Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery","volume":"103","author":"Subramanian","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0016-5085(03)00883-7","article-title":"Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients","volume":"125","author":"Aberra","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00054725-200209000-00001","article-title":"Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications","volume":"8","author":"Mahadevan","year":"2002","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib64","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ibd.20863","article-title":"Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis","volume":"15","author":"Ferrante","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.mcna.2009.08.016_bib65","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s11605-008-0630-8","article-title":"Perioperative treatment with infliximab in patients with Crohn disease and ulcerative colitis is not associated with an increased rate of postoperative complications","volume":"12","author":"Kunitake","year":"2008","journal-title":"J Gastrointest Surg"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib66","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","article-title":"The risk of post-operative complications associated with infliximab therapy for Crohn disease: a controlled cohort study","volume":"19","author":"Marchal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.mcna.2009.08.016_bib67","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s10350-007-9008-3","article-title":"Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?","volume":"50","author":"Schluender","year":"2007","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","article-title":"Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis","volume":"204","author":"Selvasekar","year":"2007","journal-title":"J\u00a0Am Coll Surg"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib69","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s10350-008-9364-7","article-title":"Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy","volume":"51","author":"Mor","year":"2008","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.mcna.2009.08.016_bib70","doi-asserted-by":"crossref","first-page":"A188","DOI":"10.1016\/S0016-5085(09)60845-3","article-title":"Pre-operative infliximab exposure and the occurrence of post-operative complications following proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis","volume":"136","author":"Swoger","year":"2009","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib71","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cgh.2007.04.007","article-title":"Risk for active tuberculosis in inflammatory bowel disease patients","volume":"5","author":"Aberra","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.mcna.2009.08.016_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib73","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib74","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib75","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.mcna.2009.08.016_bib76","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2009.08.016_bib77","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.mcna.2009.08.016_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","author":"Rahier","year":"2009","journal-title":"J Crohn Colitis"},{"key":"10.1016\/j.mcna.2009.08.016_bib79","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.mcna.2009.08.016_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","article-title":"Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease","volume":"27","author":"Theis","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib81","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib82","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases","volume":"46","author":"Gluck","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib83","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005176-200204000-00018","article-title":"Listeria meningitis after treatment with infliximab","volume":"34","author":"Kamath","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib85","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1503\/cmaj.1040563","article-title":"Cutaneous nocardiosis complicating management of Crohn disease with infliximab and prednisone","volume":"171","author":"Singh","year":"2004","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib86","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib87","first-page":"1558","article-title":"An unusual complication of immunosuppressive therapy in inflammatory bowel disease","volume":"92","author":"Khatchatourian","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.mcna.2009.08.016_bib88","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00535-004-1454-2","article-title":"Pneumocystis carinii pneumonia in patients with ulcerative colitis","volume":"39","author":"Takenaka","year":"2004","journal-title":"J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib89","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJM199208133270714","article-title":"Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis","volume":"327","author":"Smith","year":"1992","journal-title":"N Engl J Med"},{"issue":"7077","key":"10.1016\/j.mcna.2009.08.016_bib90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bmj.314.7077.363","article-title":"Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia","volume":"314","author":"Quan","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mcna.2009.08.016_bib91","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00054725-200407000-00017","article-title":"Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn disease","volume":"10","author":"Seddik","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.mcna.2009.08.016_bib92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib93","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn sdisease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"18","key":"10.1016\/j.mcna.2009.08.016_bib94","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2009.08.016_bib95","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib96","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib98","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib99","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1157\/13062892","volume":"27","author":"Belda","year":"2004","journal-title":"Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","article-title":"Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?","volume":"24","author":"De Rosa","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib101","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/377235","article-title":"Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists","volume":"37","author":"Gottlieb","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.mcna.2009.08.016_bib102","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib103","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00054725-200409000-00035","article-title":"Infliximab therapy in a patient with Crohn disease and chronic hepatitis B virus infection","volume":"10","author":"del Valle Garcia-Sanchez","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib104","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mcna.2009.08.016_bib105","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib106","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib107","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.rhu.0000260411.75599.39","article-title":"Successful etanercept use in an HIV-positive patient with rheumatoid arthritis","volume":"13","author":"Kaur","year":"2007","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"issue":"RR-2","key":"10.1016\/j.mcna.2009.08.016_bib110","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.mcna.2009.08.016_bib111","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/0003-4819-150-1-200901060-00008","article-title":"Recommended adult immunization schedule: United States, 2009","volume":"150","author":"Advisory Committee on Immunization Practices","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.mcna.2009.08.016_bib113","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1157\/13119881","volume":"31","author":"Bargallo","year":"2008","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mcna.2009.08.016_bib114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00054725-200403000-00004","article-title":"Epstein-Barr virus viral load in Crohn disease: effect of immunosuppressive therapy","volume":"10","author":"Reijasse","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib115","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/425123","article-title":"Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis","volume":"39","author":"Haerter","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.mcna.2009.08.016_bib116","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-200212000-00018","article-title":"Disseminated cytomegalovirus infection in Crohn disease following anti-tumour necrosis factor therapy","volume":"14","author":"Helbling","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.mcna.2009.08.016_bib117","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/j.1572-0241.2006.00869.x","article-title":"Cytomegalovirus colitis complicating inflammatory bowel disease","volume":"101","author":"Kandiel","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mcna.2009.08.016_bib118","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1572-0241.2001.03949.x","article-title":"Outcome of cytomegalovirus infections in patients with inflammatory bowel disease","volume":"96","author":"Papadakis","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib119","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2009.08.016_bib120","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatology (Oxford)"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712509001175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712509001175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T02:54:12Z","timestamp":1558666452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712509001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0025712509001175"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2009.08.016","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}